Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTENNIS: Toripalimab with Chemotherapy in Early TNBC
NCT04418154Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Jun 2020; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04418154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418154.